Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression
Llibre Codina, Josep Maria (Fundació Lluita contra les Infeccions)
Cozzi-Lepri, Alessandro (University College London, UK)
Pedersen, Court (Odense University Hospital (Dinamarca))
Ristola, Matti (Helsinki University Hospital (Finlàndia))
Losso, Marcelo (Hospital General de Agudos JM Ramos Mejía, Buenos Aires, Argentina)
Mocroft, Amanda (University College London, UK)
Mitsura, Viktar (Gomel State Medical University, Belarus)
Falconer, Karolin (Karolinska University Hospital and Karolinska Institutet (Suècia))
Maltez, Fernando (Curry Cabral Hospital, Lisboa, Portugal)
Beniowski, Marek (Specialistic Hospital, Chorzów, Poland)
Vullo, Vincenzo (Policlinico Umberto 1, Rome, Italy)
Hassoun, Gamal (Rambam-Health Care Campus, Haifa, Israel)
Kuzovatova, Elena (Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina, Russia)
Szlavik, János (St László Hospital (Hongria))
Kuznetsova, Anastasiia (Kharkov State Medical University, Ukraine)
Stellbrink, Hans-Jürgen (ICH Study Center, Hamburg, Germany)
Duvivier, Claudine (Hôpital Necker Enfants Malades (París, França))
Edwards, Simon (Mortimer Market Centre, UK)
Laut, Kamilla (Centre for Health & University of Copenhagen, Denmark)
Paredes, Roger (IrsiCaixa)

Date:	2016
Abstract:	Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR <50 copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL.
Grants:	European Commission 260694
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució i la comunicació pública de l'obra, sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Atazanavir ; HIV-1 ; Protease inhibitors: abacavir ; Simplification antiretroviral therapy
Published in:	Medicine, Vol. 95, Num. 40 (october 2016) , ISSN 1536-5964

DOI: 10.1097/MD.0000000000005020
PMID: 27749561

7 p, 214.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles